Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
166.95 USD   +3.15%
06/30BEIGENE : Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma - Form 8-K
PU
06/30BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/30BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3 Trial
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Rating

05/09/2022 | 12:17pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about BEIGENE, LTD.
06/30BEIGENE : Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tis..
PU
06/30BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/30BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3..
MT
06/30BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti..
BU
06/30BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti..
CI
06/27BeiGene Grants Share Options, Restricted Share Units
MT
06/26Antengene Corporation Limited Announces Clinical Trial Collaboration with BeiGene, Ltd...
CI
06/24Asian ADRs Climb Higher in Friday Trading
MT
06/22BEIGENE : Announces Acceptance of Supplemental Biologics License Application in China for ..
PU
06/22INSIDER SELL : Beigene
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 426 M - -
Net income 2022 -1 421 M - -
Net cash 2022 2 911 M - -
P/E ratio 2022 -11,2x
Yield 2022 -
Capitalization 17 253 M 17 253 M -
EV / Sales 2022 10,1x
EV / Sales 2023 7,40x
Nbr of Employees 8 300
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 166,95 $
Average target price 308,10 $
Spread / Average Target 84,5%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-38.38%17 253
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
WUXI APPTEC CO., LTD.-13.31%44 566
BIONTECH SE-38.91%38 276